Keyword: Merck KGaA

In this week's EuroBiotech Report, Bayer pumps $150 million into cell therapies, Merck KGaA retools F-star pact and Philogen raises $70 million. 

The Big Pharma has exercised its option on a discovery program but walked away from phase 1 LAG-3 PD-L1 bispecific FS118.

Gilman to be full-time CEO of Arrakis, while Wotton takes over Obsidian; ex-GSK immunology chief to lead Kintai Therapeutics; and Insys swaps CEOs.

In this week's EuroBiotech Report, Bayer moves into Kendall Square, Poxel's shares jump, Kymab grabs former German Merck executive and more.

Shire R&D chief jumps ship to Ironwood spinout; Daiichi taps new CEO; and Kymab nabs new CEO from Merck KGaA.

Syndax’s entinostat missed its primary endpoints in two phase 1b/2 trials combining it with anti-PD-1 drugs from Genentech and Merck KGaA and Pfizer.

GlaxoSmithKline is cutting a host of unwanted investigational drugs as it joins other Big Pharmas in the fourth-quarter clearout.

Merck, which partnered with Pfizer on Bavencio, went to another Big Pharma for developmental work on a next-generation I-O drug to take on Keytruda.

Merck KGaA and Tencent will work to develop AI-based platforms to help increase access to healthcare services and promote disease awareness.

Merck licensed the drugs for $230 million upfront two years ago but has now granted Vertex the right to use them in certain gene-editing applications.